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Currently DNA-based analysis of blood groups is mainly used to 
improve transfusion safety by reducing alloantibody formation 
in multiply transfused patients and by monitoring pregnancies at 
risk for hemolytic disease of the fetus and newborn. We present a 
case in which genotyping was performed after massive transfusion 
with unmatched group O, D– blood in a trauma setting. Our 
patient was genotyped as O1A1 and predicted to be D–, and we 
therefore transfused group A, D– red blood cell concentrates. 
This case demonstrates how the use of blood group genotyping 
in an acute setting can lead to a decrease in the unnecessary 
use of group O, D– blood products. Immunohematology 
2012;28:85–7.
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Case Report
Our transfusion laboratory received an emergency 
request for six unmatched group O, D– red blood cell (RBC) 
concentrates for a patient. These units were to be transfused 
not inside the hospital but at the scene of a car accident (at a 
peripheral highway), where the patient was bleeding heavily 
while trapped in a car wreck. Again, another four unmatched 
RBC units were ordered together with five group AB, D– 
fresh-frozen plasma (FFP) units and one randomly selected 
unit of platelets obtained from five donors. All products were 
leukocyte reduced, with less than 106/L white blood cells per 
unit. We had not received blood for crossmatching.
When released from the car wreck, the 62-year-old white 
female patient arrived at the hospital emergency department 
and was admitted to the operating room immediately. The 
patient suffered from complex high-impact trauma. Her car 
had slid underneath a truck, and the patient had been trapped 
for at least 1.5 hours. She had multiple fractures, in the nose, 
left wrist, left humerus, bilateral femur, and ramus superior 
and inferior, and she had a pneumothorax. Also, the patient 
exhibited various superficial wounds and a head injury that 
was closed using staples. Besides damage-control surgery, 
additional acute surgery was necessary to implant a stent 
because of dissection of the descending aorta. During this 
procedure the patient was in need of more blood products, and 
at that time the transfusion laboratory received the first sample 
for crossmatching. Serologically it was no longer possible to 
determine a blood group owing to the number of transfused 
RBC units. Even a mixed-field reaction was hardly visible 
(Fig. 1). Also, a reverse blood group typing was not possible as 
a result of the number of FFP units she had received. After the 
surgical procedure, the patient was stable and was transferred 
to the intensive care unit with a hemoglobin concentration of 
8.8 g/dL (5.5 mmol/L). Three additional FFP units and two 
five-donor platelet concentrates were transfused because 
of low levels of fibrinogen (0.87 g/L) and platelets (76/nL), 
respectively. Altogether, our patient received 18 units of group 
O, D– leukocyte-reduced packed cells, 12 units of FFP (blood 
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Fig. 1. Blood group typing cards (Ortho Clinical Diagnostics, Inc., 
Raritan, NJ) from our patient’s blood upon arrival at the hospital, 
showing a mixed-field reaction with anti-A (left lane). The mixed-
field reaction was only visible after addition of 10x the erythrocyte 
volume used in the usual procedure. No reaction with the A1 cells 
and B cells (Ortho Clinical Diagnostics, Inc.) is visible.
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group AB), and 6 units of leukocyte-reduced five-donor platelet 
concentrates (group O, D–) during her intensive care stay.
Unfortunately, we were unable to obtain information 
regarding the blood group of our patient (even after contacting 
the patient’s general practitioner and the local blood bank). 
Therefore, we chose to determine her blood group by means 
of DNA analysis to avoid further (unnecessary) use of group 
O, D– RBC products. We collected venous blood samples 
(anticoagulated in K3-EDTA) and sent them to the laboratories 
of the Sanquin Blood Supply Foundation. ABO genotyping 
was performed using a sequence-specific primer polymerase 
chain reaction (SSP-PCR).1 RHD genotyping was performed 
using a multiplex reverse transcriptase (RT) PCR method.2 
Our patient’s genotype was determined to be O1A1, and she 
was predicted to be D–.
Fortunately, the patient appeared to no longer need blood 
products. She stayed in the intensive care unit for another 20 
days, during which time only one unit of RBCs was transfused 
(blood group A, D–). At that time the patient’s blood sample 
was serologically typed as group A, D– (without mixed-field 
reactions), and the screening for irregular antibodies was 
negative (using a three-cell screening panel, Ortho Clinical 
Diagnostics, Inc.). She was then moved to the surgery 
department for necrotomy of wounds and was transferred to a 
nursing home 2 months after the car accident.
Results
The chosen SSP-PCR is based on the presence of O1, 
O2, B, or A2 genes (the presence of glucosyltransferases 
on chromosome 9q34-2) in DNA isolated from peripheral 
blood samples.1 A PCR product is produced only when the 
specific chosen primer binds to and amplifies the sequence 
of interest. Eight mixtures of four allele-specific primer sets 
are used. The PCR products are transferred to an ethidium-
bromide gel, and patterns are read and interpreted manually. 
Extrapolating results of eight different incubations (O1, O2, B, 
A2, non-O1, non-O2, non-B, and non-A2) led to the genotype. 
Therefore, this assay cannot be used for ABO variant analysis. 
In our case, blood group A1 was predicted as determined by 
exclusion of the other genotypes present. This phenotype has a 
frequency of 33 percent in the white population. The presence 
of an A2 blood group was excluded, as was the presence of a 
B or Bombay (Oh) phenotype. The frequency of other type A 
(or B) blood groups is very rare in the white population, and 
would not have led to a mixed-field reaction of the patient’s 
RBCs with the anti-A serum (Fig. 1).
We were not able to confirm the blood group by reverse 
blood typing because of the amount of FFP received. However, 
after several days, serum anti-B was found but no anti-A; this 
is consistent with the ABO genotype we found.
The multiplex PCR for genotyping the Rh blood group 
system is based on single-nucleotide polymorphisms (SNPs) 
using six different primer sets that cover exons 3, 4, 5, 6, 7, and 
9 of RHD and is able to identify most RHD variants.2 Based on 
the genotyping results, our patient was predicted to be D– , 
and for our white patient, the frequency of RHDψ or a variant 
D is very low. We did not confirm genotyping with buccal cells 
because the clinical consequences of a false-negative result are 
far less severe than those of a false-positive result. Serologically, 
on increasing volumes of RBCs to observe mixed-field 
reaction in our column technique, the D phenotype remained 
negative (Fig. 1). When blood group serology was repeated 
before transfusion 2 weeks after the accident, no mixed-field 
agglutination was observed, although transfused RBCs were 
likely to have been present. This was consistent with a D– 
phenotype and showed concordance between genotype and 
phenotype results. Again, using a three-cell screening panel, 
we found no irregular erythrocyte antibodies.
Of course, interpretation of genotyping results should be 
performed carefully because ethnic differences (e.g., presence 
of RHDψ, or the DAR variant) and silencing alleles (e.g., GATA 
box mutations) exist that could lead to discrepancies between 
genotype and phenotype.3,4 When the patient is of a certain 
ethnicity with a higher risk of ABO variants, sequencing may 
be an option, although costly and time-consuming.
Discussion
Recently, excellent reviews5,6 have been published 
regarding genotyping of the blood donor population and 
its possible drawbacks. However, in transfusion practice, 
genotyping is not commonly performed on patient samples. 
The Dutch national guideline currently states that a blood 
group can only be confirmed when it has been established 
by testing two different samples, irrespective of the method 
used.7 One method may be genotyping.
From 2001, leukocytes are depleted from all blood products 
within the Netherlands by means of filtration, resulting in the 
presence of less than 1 × 106 white blood cells per unit. In case 
of massive transfusion of RBCs and platelet or plasma units, 
the load of donor white blood cells in the patient remains low 
(undetectable when compared with the patient’s white blood 
cell count, on average 5 × 109/L), hence genotyping on DNA 
from the patient’s white blood cells is achievable. Our patient 
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had a white blood cell count of 4.5 leukocytes/nL at the time of 
DNA analysis. Of these, a maximum of 4 percent (0.16/nL: 16 
blood products times 106 white blood cells) could potentially 
originate from the received RBC units. To circumvent these 
limitations or when white blood cell counts in peripheral blood 
are too low to perform genotyping, other material can be used, 
such as nails or buccal epithelial cells (with potential errors 
in bone marrow transplant patients).3,4,8 Therefore, leukocyte 
counting for the patient is essential before performing these 
analyses, and care should be taken in case of neutropenic or 
lymphopenic patients.
Ideally, all transfusions should be closely monitored, 
especially transfusions of unmatched RBC units, to detect acute 
transfusion reactions in case of transfusion of incompatible 
blood group(s). Unfortunately the clinical practice shows that 
unmatched units are transfused in emergency situations, in 
which close monitoring of transfusion can be difficult. Because 
transfused RBCs remain in circulation for several weeks and 
can cause mixed-field agglutination when antigen typing 
is performed, genotyping can determine the blood group of 
trauma patients who have received repeated unmatched RBC 
units. 
Conclusions
As has previously been suggested, blood group 
genotyping can be helpful in acute situations, when serologic 
(hemagglutination with antisera) blood group typing is 
not possible or yields inconclusive results (i.e., mixed-field 
agglutination, discrepant results).6,8 The success of genotyping 
in cases of emergency depends on the speed of processing and 
the turnaround time. Improvements in these will eventually 
lead to fewer unmatched transfusions. The blood transfusion 
laboratory should, however, always be aware of the limitations 
of genotyping (vs. serologic determination of blood groups). In 
a trauma center, genotyping a patient’s sample to determine 
ABO and D might be a suitable alternative to transfusing 
group O, D– RBCs, thus reducing the unnecessary use of such 
blood products. 
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